Aptose Biosciences (TSE:APS) has released an update.
Aptose Biosciences has announced that its new triplet therapy protocol for treating newly diagnosed AML patients has been approved by the FDA to proceed. Furthermore, an abstract on the therapy’s safety and efficacy has been submitted for presentation at an upcoming ASH annual meeting. The company also addressed a Nasdaq deficiency notice regarding its share price.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.
